Some people may have other conditions, like metabolic liver disease or kidney issues, which retatrutide is being studied for, so these could impact the doctors recommendation
2.0 mg) may intensify side effects Some patients experienced gastroparesis at lower doses Others didnt develop problems until higher doses Your specific dosage history is crucial evidence 3
Only 8% of the total cohort were low early responders, and of those, just 23% eventually reached 15% total weight loss
Improves intestinal transit time and stool frequency
If you havent had lab work done in the last year, labs will be ordered for your care team to gain insights into your unique metabolism so that you can work together to shape a personalized care plan
Dan Skovronsky, Lillys Chief Scientific and Product Officer, described the results as extraordinary